StockTake: Another country under the belt

Orthocell are set to start selling Striate+ in Germany, Austria and Switzerland gaining exposure to European markets.

Orthocell (ASX:OCC) is set to kick off sales in Germany, Austria and Switzerland for its dental guided bone and tissue regeneration product Striate+, gaining exposure to a market valued over $1 billion. 

Watch the video to hear more.

This video was developed in collaboration with Orthocell, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.